Unknown

Dataset Information

0

Cell-cell communication network-based interpretable machine learning predicts cancer patient response to immune checkpoint inhibitors.


ABSTRACT: Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment. However, only some patients respond to ICIs, and current biomarkers for ICI efficacy have limited performance. Here, we devised an interpretable machine learning (ML) model trained using patient-specific cell-cell communication networks (CCNs) decoded from the patient's bulk tumor transcriptome. The model could (i) predict ICI efficacy for patients across four cancer types (median AUROC: 0.79) and (ii) identify key communication pathways with crucial players responsible for patient response or resistance to ICIs by analyzing more than 700 ICI-treated patient samples from 11 cohorts. The model prioritized chemotaxis communication of immune-related cells and growth factor communication of structural cells as the key biological processes underlying response and resistance to ICIs, respectively. We confirmed the key communication pathways and players at the single-cell level in patients with melanoma. Our network-based ML approach can be used to expand ICIs' clinical benefits in cancer patients.

SUBMITTER: Lee J 

PROVIDER: S-EPMC10830106 | biostudies-literature | 2024 Feb

REPOSITORIES: biostudies-literature

altmetric image

Publications

Cell-cell communication network-based interpretable machine learning predicts cancer patient response to immune checkpoint inhibitors.

Lee Juhun J   Kim Donghyo D   Kong JungHo J   Ha Doyeon D   Kim Inhae I   Park Minhyuk M   Lee Kwanghwan K   Im Sin-Hyeog SH   Kim Sanguk S  

Science advances 20240131 5


Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment. However, only some patients respond to ICIs, and current biomarkers for ICI efficacy have limited performance. Here, we devised an interpretable machine learning (ML) model trained using patient-specific cell-cell communication networks (CCNs) decoded from the patient's bulk tumor transcriptome. The model could (i) predict ICI efficacy for patients across four cancer types (median AUROC: 0.79) and (ii) identify key communi  ...[more]

Similar Datasets

2018-04-07 | GSE112798 | GEO
| S-EPMC10582499 | biostudies-literature
2024-01-27 | GSE230012 | GEO
| S-EPMC5553725 | biostudies-other
| S-EPMC11531944 | biostudies-literature
| S-EPMC9620606 | biostudies-literature
| S-EPMC10950216 | biostudies-literature
2024-01-28 | GSE230006 | GEO
2024-01-28 | GSE230011 | GEO
2024-01-28 | GSE230010 | GEO